Get the Stockscreener App
6.67
8.25%
-0.60
Sagimet Biosciences Inc stock is traded at $6.67, with a volume of 1.51M.
It is down -8.25% in the last 24 hours and down -14.27% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.27
Open:
$6.85
24h Volume:
1.51M
Relative Volume:
2.81
Market Cap:
$206.78M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-5.6239
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-13.94%
1M Performance:
-14.27%
6M Performance:
+107.14%
1Y Performance:
+48.22%
1-Day Range:
$6.32
$7.01
1-Week Range:
$6.32
$8.15
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.67 | 236.43M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences executive chairman sells $290k in shares By Investing.com - Investing.com Australia
Sagimet Biosciences executive chairman sells $290k in shares - Investing.com
Will Sagimet Biosciences Inc. (0O2) stock sustain bullish trend into 2025Weekly Stock Recap & AI Enhanced Market Trend Forecasts - newser.com
Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025 - Quiver Quantitative
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewswire
Why Sagimet Biosciences Inc. (0O2) stock attracts wealthy investorsMarket Risk Summary & Growth Focused Investment Plans - newser.com
Can Sagimet Biosciences Inc. (0O2) stock attract analyst upgradesPortfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
What catalysts could drive Sagimet Biosciences Inc. stock higherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
Is Sagimet Biosciences Inc. (0O2) stock worth holding before Fed meetingWeekly Trade Recap & Fast Entry Momentum Trade Alerts - newser.com
Detecting support and resistance levels for Sagimet Biosciences Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Sagimet Biosciences Inc (0O2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Sagimet Biosciences Inc. (0O2) stock a buy during volatile marketsJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
How sustainable is Sagimet Biosciences Inc. stock dividend payoutJuly 2025 Short Interest & Safe Capital Allocation Plans - newser.com
Identifying reversal signals in Sagimet Biosciences Inc.Rate Cut & Fast Exit and Entry Trade Guides - newser.com
Reversal indicators forming on Sagimet Biosciences Inc. stockWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
How cyclical is Sagimet Biosciences Inc. (0O2) stock compared to rivalsJuly 2025 Pullbacks & Growth Focused Stock Reports - newser.com
Published on: 2025-11-19 02:00:25 - newser.com
Will Sagimet Biosciences Inc. rebound enough to break evenGap Down & Comprehensive Market Scan Reports - newser.com
How Sagimet Biosciences Inc. (0O2) stock trades after earningsAnalyst Downgrade & Real-Time Buy Signal Alerts - newser.com
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha
Is Sagimet Biosciences Inc. stock resilient to inflation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Sagimet Biosciences, Inc.: Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
How Sagimet Biosciences Inc. stock compares to market leadersOptions Play & Daily Growth Stock Tips - newser.com
Key metrics from Sagimet Biosciences Inc.’s quarterly dataInsider Buying & Weekly Stock Performance Updates - newser.com
What does recent volatility data suggest for Sagimet Biosciences Inc.2025 Biggest Moves & Precise Buy Zone Identification - newser.com
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):